Melanoma, resistant chronic myelocytic leukemia & recurrent, metastatic or inoperable carcinoma of the ovary. Used concomitantly w/ irradiation therapy in primary squamous cell (epidermoid) carcinomas of the head & neck (excluding the lip) & carcinoma of the cervix.
Solid tumors Continuous therapy: 20-30 mg/kg daily as a single dose. Intermittent therapy: 80 mg/kg as single doses given every 3rd day. Carcinoma of the head, neck & cervix Concomitant therapy w/ irradiation: 80 mg/kg in single doses given every 3rd day. Resistant chronic myelocytic leukemia Continuous therapy: 20-30 mg/kg daily as a single dose.
Close supervision in hydroxyurea therapy eg, complete blood & bone marrow exam (interrupt therapy until values rise significantly to normal level), kidney & liver function. Renal dysfunction. Avoid concomitant use w/ didanosine & stavudine.